SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE: NVTA), a genetic information company, today announced it now offers genetic testing for neuromuscular diseases, including Duchenne/Becker ...
Researchers review pulmonary function testing measures that span 4 categories that can assess the respiratory muscle dysfunction that happens in diseases like spinal muscular atrophy (SMA). Muscle ...
(HealthDay)—Targeted panel testing has the highest clinical yield for molecular diagnosis of neuromuscular diseases (NMDs), according to a study published in the February issue of the Annals of ...
In neuromuscular diseases, neurons and muscle cells stop communicating properly. Researchers led by Mina Gouti can now model this in 2D in a culture dish. Writing about their findings in Nature ...
Invitae boosted its genetic testing menu with a new test for the diagnosis of spinal muscular atrophy, the second-leading genetic disease in infants. The test provides “significant improvements” over ...
A new genetic test targeting the most common types of muscular dystrophy -- those caused by mutations in the dystrophin gene -- is far quicker with greater accuracy and sensitivity than existing tests ...
SAN FRANCISCO, March 23, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company today announced its partnership with the Muscular Dystrophy Association (MDA) to offer sponsored, ...
The team genetically modified the neurons in the device to respond to light. By shining light directly on the neurons, they can precisely stimulate these cells, which in turn send signals to excite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results